

Reuben Benjamin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7867388/publications.pdf>

Version: 2024-02-01

40
papers

988
citations

567281

15
h-index

454955

30
g-index

44
all docs

44
docs citations

44
times ranked

2006
citing authors

#	ARTICLE	IF	CITATIONS
1	Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. <i>Lancet</i> , The, 2020, 396, 1885-1894.	13.7	206
2	Allogeneic CAR-T Cells: More than Ease of Access?. <i>Cells</i> , 2018, 7, 155.	4.1	129
3	Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. <i>Cancer Cell</i> , 2021, 39, 257-275.e6.	16.8	93
4	Poor outcome and prolonged persistence of SARS-CoV-2 RNA in COVID-19 patients with haematological malignancies; King's College Hospital experience. <i>British Journal of Haematology</i> , 2020, 190, e279-e282.	2.5	89
5	LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. <i>Leukemia</i> , 2022, 36, 1371-1376.	7.2	81
6	Secondary HLH is uncommon in severe COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e283-e285.	2.5	44
7	Risk of COVID-19 death in cancer patients: an analysis from Guy's Cancer Centre and King's College Hospital in London. <i>British Journal of Cancer</i> , 2021, 125, 939-947.	6.4	41
8	Early FDG-PET response predicts CAR-T failure in large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 321-326.	5.2	37
9	Cancer immunotherapy with CAR-T cells " behold the future. <i>Clinical Medicine</i> , 2018, 18, 324-328.	1.9	32
10	Real-world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi-centre UK experience. <i>British Journal of Haematology</i> , 2017, 176, 908-917.	2.5	25
11	Language dysfunction-associated EEG findings in patients with CAR-T related neurotoxicity. <i>BMJ Neurology Open</i> , 2020, 2, e000054.	1.6	18
12	Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study. <i>Blood</i> , 2019, 134, 693-693.	1.4	18
13	Effect of age and frailty on the efficacy and tolerability of once-weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>American Journal of Hematology</i> , 2021, 96, 708-718.	4.1	16
14	Preclinical toxicology and safety pharmacology of the first-in-class GADD45 ² /MKK7 inhibitor and clinical candidate, DTP3. <i>Toxicology Reports</i> , 2019, 6, 369-379.	3.3	15
15	Risk of relapse of multiple myeloma following kidney transplantation. <i>CKJ: Clinical Kidney Journal</i> , 2019, 12, 216-223.	2.9	15
16	Clinical proof of concept for a safe and effective NF- κ B-targeting strategy in multiple myeloma. <i>British Journal of Haematology</i> , 2019, 185, 588-592.	2.5	15
17	Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk. <i>American Journal of Hematology</i> , 2021, 96, 1120-1130.	4.1	15
18	Effect of prior treatments on selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2021, 14, 59.	17.0	11

#	ARTICLE	IF	CITATIONS
19	What are the difficulties in conducting randomised controlled trials of thromboprophylaxis in myeloma patients and how can we address these? Lessons from apixaban versus LMWH or aspirin as thromboprophylaxis in newly diagnosed multiple myeloma (TiMM) feasibility clinical trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 48, 315-322.	2.1	8
20	Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study. <i>British Journal of Haematology</i> , 2021, 193, 750-760.	2.5	8
21	Allogeneic Anti-BCMA CAR T Cells Are Superior to Multiple Myeloma-derived CAR T Cells in Preclinical Studies and May Be Combined with Gamma Secretase Inhibitors. <i>Cancer Research Communications</i> , 2022, 2, 158-171.	1.7	8
22	Human Herpesvirus 6 Encephalitis Following Axicabtagene Ciloleucel Treatment for Refractory Diffuse Large B Cell Lymphoma. <i>HemaSphere</i> , 2021, 5, e535.	2.7	7
23	Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E383-E386.	4.1	7
24	Efficacy and Safety of Carfilzomib at 56mg/m2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study. <i>Blood</i> , 2019, 134, 861-861.	1.4	7
25	Efficacy and tolerability of <sc>onceâ€week</sc> selinexor, bortezomib, and dexamethasone in comparison with standard <sc>twiceâ€week</sc> bortezomib and dexamethasone in previously treated multiple myeloma with renal impairment: Subgroup analysis from the <sc>BOSTON</sc> study. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	7
26	Autologous stem cell transplantation for multiple myeloma patients with chronic kidney disease: a safe and effective option. <i>Bone Marrow Transplantation</i> , 2022, 57, 959-965.	2.4	7
27	Clinical Outcomes in Patients (Pts) with Dose Reduction of Selinexor in Combination with Bortezomib, and Dexamethasone (XVd) in Previously Treated Multiple Myeloma from the Boston Study. <i>Blood</i> , 2021, 138, 3793-3793.	1.4	6
28	Progression-Free Survival (PFS) Benefit Demonstrated and Quality of Life (QoL) Maintained across Age and Frailty Subgroups with the Oral Proteasome Inhibitor (PI) Ixazomib Vs Placebo As Post-Induction Maintenance Therapy in Non-Transplant Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Analysis of the TOURMALINE-MM4 Phase 3 Trial. <i>Blood</i> , 2020, 136, 30-31.	1.4	6
29	Trends in Autologous Transplantation for Myeloma in EBMT Centres between 1993 and 2017. <i>Blood</i> , 2019, 134, 4575-4575.	1.4	3
30	Once Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma: High-Risk Cytogenetic Risk Planned Subgroup Analyses from the Phase 3 Boston Study. <i>Blood</i> , 2020, 136, 35-36.	1.4	3
31	Once Weekly Selinexor, Bortezomib, and Dexamethasone Versus Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Age and Frailty Subgroup Analyses from the Phase 3 Boston Study. <i>Blood</i> , 2020, 136, 17-18.	1.4	3
32	The combination of an inclusive novel agent treatment strategy, pre-emptive therapy dose reduction, and prolonged therapy results in good outcomes in elderly myeloma patients. <i>British Journal of Haematology</i> , 2019, 186, e11-e13.	2.5	1
33	Impact of Prior Therapies on the Safety and Efficacy of Once Weekly Selinexor, Bortezomib, and Dexamethasone Compared with Twice Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Results from the Boston Study. <i>Blood</i> , 2020, 136, 50-52.	1.4	1
34	Effects of Cytogenetic Risk on Outcomes in Multiple Myeloma Treated with Selinexor, Bortezomib, and Dexamethasone (XVd). <i>Blood</i> , 2021, 138, 1634-1634.	1.4	1
35	Peripheral Neuropathy Symptoms, Pain and Functioning in Relapsed or Refractory Multiple Myeloma Patients Treated with Selinexor, Bortezomib, and Dexamethasone. <i>Blood</i> , 2020, 136, 39-41.	1.4	1
36	Subgroup analyses in patients with relapsed/refractory multiple myeloma (RRMM) receiving real-life current standard of care (SOC) in the LocoMMotion study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8031-8031.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Real-World Use of Pomalidomide and Dexamethasone in Double Refractory Multiple Myeloma: A Multicentre UK Experience. <i>Blood</i> , 2016, 128, 3312-3312.	1.4	0
38	Investigation of Allogeneic TTM Targeting CD70 As a Potential Therapy for an Array of Hematological Malignancies. <i>Blood</i> , 2019, 134, 5157-5157.	1.4	0
39	PET-CT for Assessment of Multiple Myeloma Disease Burden and Metabolic Response before and after Carfilzomib-Based Induction, Consolidation and Carfilzomib Maintenance Therapy: Data from the UK NCRI Cardamon Study. <i>Blood</i> , 2021, 138, 2750-2750.	1.4	0
40	Effect of Prior Treatment with Proteasome Inhibitors on the Efficacy and Safety of Once-Weekly Selinexor, Bortezomib, and Dexamethasone in Comparison with Twice-Weekly Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Subgroup Analysis from the Boston Study. <i>Blood</i> , 2020, 136, 48-50.	1.4	0